News

As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical

The Notice of Allowance is for U.S. Patent Application No. 14/230,053, "Compositions for Treatment of Attention Deficit Hyperactivity Disorder" owned by Highland’s wholly owned subsidiary, Ironshore Pharmaceuticals &

The grant, with additional funding from Heptares, will support a three-year research project aimed at developing first-in-class, selective and orally available small molecule GLP-1 receptor antagonists for the

The inability to detect this overpouch mislabeling at the point of care may result in the administration of a dose lower than intended. In thehigh-risk patient population –

Maternal immunization is a strategy to protect newborns through the transfer of maternal antibodies via active transport mechanisms in the placenta, thus providing the infant the benefit of

The new 120,000m² facility will provide increased capacity for compounds within the company’s immunology and oncology pipelines. The Singapore site includes a contained API facility, additional buildings and

Hysingla ER is a once-daily, single-entity medication formulated using the company’s extended-release solid oral platform, RESISTEC, which uses a combination of polymer and processing that confers tablet hardness

Dupilumab is indicated for AD patients who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate. It is an investigational therapy

The company, which is focused on research, development and production of pharmaceutical, nutraceutical and cosmetic products, has executed an option agreement for a land purchase of a 5,328m²